Generex Data Presented At The Endocrine Society's Annual Meeting

• Press Release
• Source: Generex Biotechnology Corp.
• On 9:30 am EDT, Thursday June 11, 2009

WORCESTER, Mass., June 11, 2009 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT - News; www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced the presentation of clinical data at The Endocrine Society's Annual Meeting (www.endo-society.org) being held in Washington, DC, June 10 - 13, 2009. The meeting focuses on the latest advances in endocrine research and clinical care.

Related Quotes

Symbol	Price	Change
GNBT	0.48	0.00

{"s" : "gnbt","k" : "c10,l10,p20,t10","o" : "","j" : ""}

Yesterday, Generex made a poster presentation of the abstract entitled Buccal Spray Insulin for the Management of Post-Prandial Hyperglycaemia in Subjects with Impaired Glucose Tolerance authored by Professor Paolo Pozzilli, Head of the Department of Diabetes and Endocrinology at University Campus Bio-Medico, Rome, Italy, together with Andrea Palermo, Nicola Napoli, Flavia Costanza, Giusy Beretta and Silvia Manfrini). The abstract, which was the subject of a podium presentation at the recent American Diabetes Association Scientific Sessions, provides positive safety and efficacy data in respect of a phase 2 clinical trial of Generex Oral-lyn(tm), the Company's proprietary oral insulin spray product, in patients with Impaired Glucose Tolerance.

About Generex Biotechnology Corporation

Generex is engaged in the research, development and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(tm) device. The Company's flagship product, oral insulin (Generex Oral-lyn(tm)), which is available for sale in India and Ecuador for the treatment of subjects with Type-1 and Type-2 diabetes, is in Phase III clinical trials at several sites around the world. For more information, visit the Generex website at http://www.generex.com.

The Generex Biotechnology Corp. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3831

Safe Harbor Statement

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects," or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

American Capital Ventures, Inc.
Investor Relations Contact:
Howard Gostfrand
1-877-918-0774

Avalanche Strategic Communications
Media Contact:
Angelene Taccini
201-488-0049